A Decadel Leap: TCX Regimen Outperforms Standard TAC in 10-Year Survival for High-Risk HER2-Negative Breast Cancer

MedXY Editorial Team•Jan 14, 2026•news

The TCX regimen (docetaxel, cyclophosphamide, and capecitabine) achieved a significantly higher 10-year overall survival (OS) rate of 91.0% compared to 77.2% for the TAC regimen (P = 0.009).
TCX demonstrated a superior safety profile, with Grade 3-4 adverse events occurring in 42.7% of patients compared to 67.7% in the TAC group (P = 0.001).
While 10-year disease-free survival (DFS) did not reach statistical significance, disease-specific survival (DSS) was markedly improved in the TCX arm (93.9% vs. 77.8%, P = 0.002).
The findings challenge the necessity of anthracyclines in HER2-negative breast cancer populations where DNA topoisomerase IIα co-amplification is absent.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The TCX regimen (docetaxel, cyclophosphamide, and capecitabine) achieved a significantly higher 10-year overall survival (OS) rate of 91.0% compared to 77.2% for the TAC regimen (P = 0.009).
TCX demonstrated a superior safety profile, with Grade 3-4 adverse events occurring in 42.7% of patients compared to 67.7% in the TAC group (P = 0.001).
While 10-year disease-free survival (DFS) did not reach statistical significance, disease-specific survival (DSS) was markedly improved in the TCX arm (93.9% vs. 77.8%, P = 0.002).
The findings challenge the necessity of anthracyclines in HER2-negative breast cancer populations where DNA topoisomerase IIα co-amplification is absent.